S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:WVEWave Life Sciences Stock Price, Forecast & News

$9.29
-0.14 (-1.48 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.23
Now: $9.29
$9.50
50-Day Range
$8.76
MA: $9.96
$11.23
52-Week Range
$6.61
Now: $9.29
$39.98
Volume356,300 shs
Average Volume561,731 shs
Market Capitalization$331.95 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.06
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Read More
Wave Life Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:WVE
CUSIPN/A
Phone65-6236-3388

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.98 million
Book Value$1.86 per share

Profitability

Net Income$-193,640,000.00
Net Margins-1,150.43%

Miscellaneous

Employees250
Market Cap$331.95 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$9.29
-0.14 (-1.48 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive WVE News and Ratings via Email

Sign-up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions

How has Wave Life Sciences' stock been impacted by Coronavirus?

Wave Life Sciences' stock was trading at $8.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, WVE shares have increased by 14.4% and is now trading at $9.29.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Wave Life Sciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Wave Life Sciences
.

When is Wave Life Sciences' next earnings date?

Wave Life Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Wave Life Sciences
.

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd (NASDAQ:WVE) released its quarterly earnings data on Monday, August, 10th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by $0.12. Wave Life Sciences had a negative net margin of 1,150.43% and a negative return on equity of 219.06%.
View Wave Life Sciences' earnings history
.

What price target have analysts set for WVE?

6 brokerages have issued 1 year target prices for Wave Life Sciences' stock. Their forecasts range from $10.00 to $25.00. On average, they expect Wave Life Sciences' stock price to reach $19.20 in the next year. This suggests a possible upside of 106.7% from the stock's current price.
View analysts' price targets for Wave Life Sciences
.

Has Wave Life Sciences been receiving favorable news coverage?

Media coverage about WVE stock has been trending somewhat negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Wave Life Sciences earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Wave Life Sciences
.

Who are some of Wave Life Sciences' key competitors?

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Novavax (NVAX), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), ImmunoGen (IMGN) and Micron Technology (MU).

Who are Wave Life Sciences' key executives?

Wave Life Sciences' management team includes the following people:
  • Dr. Paul B. Bolno, Pres, CEO & Director (Age 45)
  • Dr. Christopher Francis Ph.D., Sr. VP of Corp. Devel. & Head of Emerging Areas (Age 41)
  • Dr. Chandra Vargeese, Sr. VP of Drug Discovery (Age 58)
  • Dr. Takeshi Wada, Scientific Advisor (Age 57)
  • Mr. Keith C. Regnante, Chief Financial Officer (Age 49)

What is Wave Life Sciences' stock symbol?

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (0.28%), Bessemer Group Inc. (0.22%), Russell Investments Group Ltd. (0.19%), Swiss National Bank (0.13%), Matisse Capital (0.12%) and Virtus ETF Advisers LLC (0.10%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc.
View institutional ownership trends for Wave Life Sciences
.

Which major investors are selling Wave Life Sciences stock?

WVE stock was sold by a variety of institutional investors in the last quarter, including Matisse Capital. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Gregory L Verdine, Michael A Panzara, and Paul Bolno.
View insider buying and selling activity for Wave Life Sciences
.

Which major investors are buying Wave Life Sciences stock?

WVE stock was acquired by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Goldman Sachs Group Inc., Virtus ETF Advisers LLC, Russell Investments Group Ltd., Quantitative Systematic Strategies LLC, SG Americas Securities LLC, Assenagon Asset Management S.A., and Swiss National Bank.
View insider buying and selling activity for Wave Life Sciences
.

How do I buy shares of Wave Life Sciences?

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Wave Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $9.29.

How big of a company is Wave Life Sciences?

Wave Life Sciences has a market capitalization of $331.95 million and generates $15.98 million in revenue each year. The company earns $-193,640,000.00 in net income (profit) each year or ($5.72) on an earnings per share basis. Wave Life Sciences employs 250 workers across the globe.

What is Wave Life Sciences' official website?

The official website for Wave Life Sciences is www.wavelifesciences.com.

How can I contact Wave Life Sciences?

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.